We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Rapid Test Identifies Bacteria from Blood Culture

By LabMedica International staff writers
Posted on 01 Feb 2011
Print article
A molecular based diagnostic test is now available that will identify three different Gram-negative bacteria in less than 90 minutes from positive blood cultures.

The assay uses peptide nucleic acid (PNA) probes to target species-specific ribosomal ribonucleic acid (rRNA) in live bacteria and yeast coupled with highly sensitive and specific fluorescence in situ hybridization (FISH).

The GNR Traffic Light PNA FISH test is capable of simultaneously identifying Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa directly from positive blood cultures containing Gram-negative rods. The unique properties of the noncharged, peptide backbone of PNA probes enable the use of FISH assays in exceedingly complex sample matrixes, such as blood and blood cultures, and this in turn facilitates the development of very simple, yet very accurate tests that do not require the extensive sample preparation necessary for other nucleic acid technologies.

The assay is manufactured by AdvanDX, (Woburn, MA, USA) and has received 510(k) clearance from the US Food and Drug Administration (FDA; Silver Spring, MD, USA). The test is the latest addition to AdvanDx's easy-to-use, molecular-based PNA FISH diagnostics platform designed to provide rapid, therapy-guiding results that enable clinicians to provide early, effective therapy for patients with Gram-negative bloodstream infections (BSI).

The GNR Traffic Light PNA FISH assay will enable microbiology laboratories to identify and report E. coli, K. pneumoniae, and P. aeruginosa from positive blood cultures 24-48 hours earlier than traditional methods. The rapid results will provide clinicians a "head start" on selecting appropriate and effective therapy for patients with Gram-negative bloodstream infections, which studies show may improve clinical outcomes, reduce incidence of adverse events and shorten hospital length of stay.

Related Links:
AdvanDX
FDA

Gold Member
Chagas Disease Test
CHAGAS Cassette
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Silver Member
ACTH Assay
ACTH ELISA
New
Bordetella Pertussis Molecular Assay
Alethia Pertussis

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.